Prognostic significance of imaging contrast enhancement for WHO grade II gliomas.

In this study, we investigated the prognostic value of MRI contrast enhancement (CE) at the time of histological diagnosis specifically in a selected population of WHO grade II gliomas. We reviewed 927 histologically proven WHO grade II gliomas for which contrast-enhanced MR images were available at the time of histological diagnosis. CE patterns were classified into three categories: "patchy and faint," "nodular-like," and "ring-like." CE progression over time was recorded before oncological treatment on successive MR images, when available. CE was present in 143 cases (15.9%), with 93 patchy and faint, 50 nodular-like, and no ring-like patterns. CE areas were time progressive before oncological treatment in 35 of the 56 available cases (62.5%). Regardless of its pattern, the presence of CE was not significantly associated with a worsened prognosis (p = 0.415) by univariate analysis. Only the nodular-like pattern of CE (p < 0.01) and the time-progressive CE (p < 0.001) in the available subgroup proved to be statistically associated with survival since first oncological treatment. The present results show the necessity, in cases of WHO grade II gliomas, to study CE at the time of histological diagnosis and, whenever possible, to follow its progression over time before oncological treatment. Nodular-like CE and time-progressive CE are associated with a worsened prognosis, both suggesting malignant transformation, even though histopathological examination cannot initially disclose signs of malignancy in those areas.

[1]  J H Philippon,et al.  Supratentorial low-grade astrocytomas in adults. , 1993, Neurosurgery.

[2]  E R Laws,et al.  Dysembryoplastic neuroepithelial tumor : a surgically curable tumor of young patients with intractable partial seizures. Report of thirty-nine cases , 1988 .

[3]  M. Faist,et al.  Interstitial 125I radiosurgery of supratentorial de novo WHO Grade 2 astrocytoma and oligoastrocytoma in adults , 2006, Cancer.

[4]  Pascale Varlet,et al.  Oligodendrogliomas. Part II: A new grading system based on morphological and imaging criteria , 1997, Journal of Neuro-Oncology.

[5]  B. Fisher,et al.  Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  H. Schlemmer,et al.  Fractionated stereotactic radiotherapy in low-grade astrocytomas: long-term outcome and prognostic factors. , 2003, International journal of radiation oncology, biology, physics.

[7]  Michael H Lev,et al.  Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. , 2004, AJNR. American journal of neuroradiology.

[8]  W. Huk,et al.  Supratentorial Low-Grade Glioma: Results and Prognostic Factors Following Postoperative Radiotherapy , 1999, Strahlentherapie und Onkologie.

[9]  J. Rock,et al.  Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. , 1998, Journal of neurosurgery.

[10]  S. Coca,et al.  Prognostic significance of tumor‐enhancement and angiogenesis in oligodendroglioma , 2002, Acta neurologica Scandinavica.

[11]  H. Kauczor,et al.  The role of MRI in patients with astrocytoma WHO II treated with fractionated stereotactic radiotherapy , 2004, European Radiology.

[12]  M. Gilbert,et al.  Diffusely infiltrative low-grade gliomas in adults. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  K. Skullerud,et al.  Survival, prognostic factors, and therapeutic efficacy in low-grade glioma: a retrospective study in 379 patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Michael A. Finn,et al.  Transient postictal MRI changes in patients with brain tumors may mimic disease progression. , 2007, Surgical neurology.

[15]  S. Grand,et al.  IRM des oligodendrogliomes , 2005 .

[16]  Laurent Capelle,et al.  Continuous growth of mean tumor diameter in a subset of grade II gliomas , 2003, Annals of neurology.

[17]  C. Daumas-Duport,et al.  Classification des oligodendrogliomes de l’hôpital sainte-anne: Mise au point à l’usage des études retrospectives , 2005 .

[18]  H. Duffau.  Lessons from brain mapping in surgery for low-grade glioma: insights into associations between tumour and brain plasticity , 2005, The Lancet Neurology.

[19]  A. Twijnstra,et al.  Supratentorial grade II astrocytoma: biological features and clinical course , 2003, The Lancet Neurology.

[20]  A. Bricolo,et al.  Prognostic factors in low-grade supratentorial astrocytomas: a uni-multivariate statistical analysis in 76 surgically treated adult patients. , 1995, Surgical neurology.

[21]  B. Devaux,et al.  Glioma dissemination along the corticospinal tract , 2005, Journal of Neuro-Oncology.

[22]  C. Daumas-Duport,et al.  Oligodendrogliomas. Part I: Patterns of growth, histological diagnosis, clinical and imaging correlations: A study of 153 cases , 1997, Journal of Neuro-Oncology.

[23]  P. Warnke,et al.  Correlation of Molecular Genetics with Molecular and Morphological Imaging in Gliomas with an Oligodendroglial Component , 2004, Clinical Cancer Research.

[24]  Raymond Sawaya,et al.  Prognostic significance of preoperative MRI scans in glioblastoma multiforme , 2004, Journal of Neuro-Oncology.

[25]  Laurent Capelle,et al.  Extension of paralimbic low grade gliomas: toward an anatomical classification based on white matter invasion patterns , 2006, Journal of Neuro-Oncology.

[26]  David Schiff,et al.  Low-grade gliomas: an update on pathology and therapy , 2005, The Lancet Neurology.

[27]  D. Troost,et al.  5-Year survival and clinical prognostic factors in progressive supratentorial diffuse “low-grade” astrocytoma: A retrospective analysis of 46 cases , 2005, Acta Neurochirurgica.

[28]  C. Daumas-Duport,et al.  [Reappraisal of the Sainte-Anne Hospital classification of oligodendrogliomas in view of retrospective studies]. , 2005, Neuro-Chirurgie.

[29]  A. Karim,et al.  Prognostic factors for survival in adult patients with cerebral low-grade glioma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  B. Fisher,et al.  Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. , 1999, International journal of radiation oncology, biology, physics.

[31]  Webster K. Cavenee,et al.  Pathology and genetics of tumours of the nervous system. , 2000 .

[32]  A. Ramaioli,et al.  Long-term outcome of oligodendrogliomas , 2004, Neurology.

[33]  R. Makuch,et al.  Variations in the natural history and survival of patients with supratentorial low-grade astrocytomas. , 1996, Neurosurgery.

[34]  Luc Taillandier,et al.  Prognostic value of initial magnetic resonance imaging growth rates for World Health Organization grade II gliomas , 2006, Annals of neurology.

[35]  B. Devaux,et al.  Dysembryoplastic neuroepithelial tumors: CT, MR findings and imaging follow-up: a study of 53 cases. , 2001, Journal of neuroradiology. Journal de neuroradiologie.

[36]  D. Kondziolka,et al.  Survival after stereotactic biopsy and irradiation of cerebral nonanaplastic, nonpilocytic astrocytoma. , 1995, Journal of neurosurgery.

[37]  K. Skullerud,et al.  Prognostic significance of CT contrast enhancement within histological subgroups of intracranial glioma , 1998, Journal of Neuro-Oncology.

[38]  P. Kelly,et al.  Perfusion Magnetic Resonance Imaging Predicts Patient Outcome as an Adjunct to Histopathology: A Second Reference Standard in the Surgical and Nonsurgical Treatment of Low-grade Gliomas , 2006, Neurosurgery.